Karyopharm Therapeutics Inc. (KPTI) Operating margin 2016–2025
Karyopharm Therapeutics Inc. (KPTI) operating margin by fiscal year — reported operating income divided by reported revenue.
-62.1%FY2025 · since FY2016: -71903.9% → -62.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -62.1% | +20.1 pp |
| FY2024 | -82.2% | +6.5 pp |
| FY2023 | -88.7% | +1.8 pp |
| FY2022 | -90.5% | -43.7 pp |
| FY2021 | -46.8% | +112.2 pp |
| FY2020 | -159.0% | +303.9 pp |
| FY2019 | -462.9% | +130.1 pp |
| FY2018 | -593.0% | +7540.2 pp |
| FY2017 | -8133.2% | +63770.7 pp |
| FY2016 | -71903.9% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More KPTI financial trends
KPTI RevenueKPTI Net incomeKPTI Net marginKPTI Gross profitKPTI Gross marginKPTI Operating incomeKPTI Operating cash flowKPTI Free cash flowKPTI Capital expendituresKPTI Return on equityKPTI Stock buybacksKPTI Dividends paidKPTI Total assetsKPTI Total liabilitiesKPTI Shareholders’ equityKPTI overview →